表紙
市場調査レポート

泌尿生殖器関連の各種提携契約:契約条件・合意内容

Global Genitourinary Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 250303
出版日 ページ情報 英文 500+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
泌尿生殖器関連の各種提携契約:契約条件・合意内容 Global Genitourinary Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年02月01日 ページ情報: 英文 500+ Pages
概要

当レポートでは、泌尿生殖器関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 泌尿生殖器関連の各種契約の動向

  • イントロダクション
  • 過去数年における泌尿生殖器関連の提携
  • 大手製薬会社による契約活動
  • 泌尿生殖器関連の事業に積極的でない大手製薬会社
  • 泌尿生殖器関連の提携:契約タイプ別
  • 泌尿生殖器関連の提携:産業部門別
  • 泌尿生殖器関連の提携:開発ステージ別
  • 泌尿生殖器関連の提携:技術タイプ別
  • 泌尿生殖器関連の提携:適応症別
  • 平均契約期間

第3章 主要契約

  • イントロダクション
  • 主要契約:取引額別
  • 大手製薬会社のかかわる主要契約

第4章 大手製薬会社による契約

  • イントロダクション
  • 大手製薬会社による提携契約の利用法
  • 企業プロファイル

第5章 契約ディレクトリ

  • イントロダクション
  • 契約タイプ別
    • 資産購入
    • 譲渡
    • 大手によるアウトライセンシング
    • 共同開発
    • 共同R&D
    • サービス契約
    • 共同プロモーション
    • 開発
    • 流通
    • 株式購入
    • ライセンシング
    • 訴訟
    • ローン
    • 製造
    • マーケティング
    • オプション
    • プロモーション
    • 研究
    • 和解関連
    • サブライセンス
    • 供給
    • 終了
  • 開発ステージ別
    • 創薬
    • 製剤設計
    • 上市
    • フェーズI
    • フェーズII
    • フェーズIII
    • 前臨床
    • 規制
  • 技術タイプ別
    • アッセイ
    • 生物学的化合物
    • 血液製剤
    • 細胞治療
    • デバイス
    • 創薬ツール
    • ドラッグデリバリー
    • 設備
    • 装置
    • 遺伝子治療
    • ゲノミクス
    • インプラント
    • ナノテクノロジー
    • ペプチド
    • プロテオミクス
    • 研究サービス
    • 研究サプライ
    • RNA治療
    • スクリーニング
    • 小分子

第6章 泌尿生殖器関連の契約:適応症別

  • イントロダクション
  • 適応症別
    • 泌尿生殖器
    • 急性腎損傷
    • アミロイド症
    • 慢性腎疾患
    • 膀胱炎
    • 糖尿病性腎症
    • 糖尿病
    • 頻尿
    • 失禁
    • 夜間頻尿
    • 切迫性失禁
    • 溶血性尿毒症症候群
    • 腎臓結石
    • 過活動膀胱
    • ペイロニー病
    • 多発性嚢胞腎
    • 前立腺疾患
    • 前立腺肥大
    • 前立腺炎
    • 腎不全
    • 腎炎
    • 尿路感染症(UTI)

第7章 提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2208

The Global Genitourinary Partnering 2010 to 2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies

Global Genitourinary Partnering 2010 to 2016 provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Genitourinary partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genitourinary partnering agreement structure
  • Genitourinary partnering contract documents
  • Top Genitourinary deals by value
  • Most active Genitourinary dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genitourinary deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genitourinary deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2010. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.

Report scope

Global Genitourinary Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.

Global Genitourinary Partnering 2010 to 2016 includes:

  • Trends in Genitourinary dealmaking in the biopharma industry since 2010
  • Analysis of Genitourinary deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genitourinary deal contract documents
  • Comprehensive access to over 3500 Genitourinary deal records
  • The leading Genitourinary deals by value since 2010
  • Most active Genitourinary dealmakers since 2010

In Global Genitourinary Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genitourinary Partnering 2010 to 2016 report provides comprehensive access to available deals and contract documents for over 3500 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Genitourinary rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Genitourinary Partnering 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Genitourinary deal trends since 2010
  • Access Genitourinary deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genitourinary partner companies
  • Comprehensive access to over 750 links to actual Genitourinary deals entered into by the world's biopharma companies
  • Indepth review of Genitourinary deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genitourinary opportunities
  • Uncover companies actively partnering Genitourinary opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genitourinary dealmaking

  • 2.1. Introduction
  • 2.2. Genitourinary partnering over the years
  • 2.3. Genitourinary partnering by deal type
  • 2.4. Genitourinary partnering by industry sector
  • 2.5. Genitourinary partnering by stage of development
  • 2.6. Genitourinary partnering by technology type
  • 2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Genitourinary partnering
  • 3.3. Genitourinary partnering headline values
  • 3.4. Genitourinary deal upfront payments
  • 3.5. Genitourinary deal milestone payments
  • 3.6. Genitourinary royalty rates

Chapter 4 - Leading Genitourinary deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Genitourinary partnering
  • 4.3. List of most active dealmakers in Genitourinary
  • 4.4. Top Genitourinary deals by value

Chapter 5 - Genitourinary contract document directory

  • 5.1. Introduction
  • 5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Genitourinary therapeutic target

Appendices

  • Appendix 1 - Directory of Genitourinary deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Genitourinary deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Genitourinary deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Genitourinary deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Genitourinary partnering since 2010
  • Figure 2: Genitourinary partnering by deal type since 2010
  • Figure 3: Genitourinary partnering by industry sector since 2010
  • Figure 4: Genitourinary partnering by stage of development since 2010
  • Figure 5: Genitourinary partnering by technology type since 2010
  • Figure 6: Genitourinary partnering by indication since 2010
  • Figure 7: Genitourinary deals with a headline value
  • Figure 8: Genitourinary deals with upfront payment values
  • Figure 9: Genitourinary deals with milestone payment
  • Figure 10: Genitourinary deals with royalty rates
  • Figure 11: Active Genitourinary dealmaking activity- 2010 to 2016
  • Figure 12: Top Genitourinary deals by value since 2010
Back to Top